Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -98.3% | -96.1% | – |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | – | 100% | -226.7% | 87% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -716,500% | -16,731.7% | -598.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -556,900% | -16,961.7% | -531.7% |
| EPS Diluted | -5.23 | -7.41 | -15.15 | -4.06 |
| % Growth | 29.4% | 51.1% | -273.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |